Cargando…
Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak
Background: this study aimed to determine the proportion of people living with HIV (PLWH) with anti-SARS-CoV-2 IgG antibodies in a large sample from a single HIV referral center in Rome, Italy; the time-frame included both the first and the second wave of the Italian COVID-19 pandemic; Methods: we c...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303907/ https://www.ncbi.nlm.nih.gov/pubmed/34202510 http://dx.doi.org/10.3390/diagnostics11071154 |
_version_ | 1783727202839298048 |
---|---|
author | Lombardi, Francesca Ricci, Rosalba Belmonti, Simone Fabbiani, Massimiliano Borghetti, Alberto Baldin, Gianmaria Ciccullo, Arturo Tamburrini, Enrica Visconti, Elena Sanguinetti, Maurizio Di Giambenedetto, Simona |
author_facet | Lombardi, Francesca Ricci, Rosalba Belmonti, Simone Fabbiani, Massimiliano Borghetti, Alberto Baldin, Gianmaria Ciccullo, Arturo Tamburrini, Enrica Visconti, Elena Sanguinetti, Maurizio Di Giambenedetto, Simona |
author_sort | Lombardi, Francesca |
collection | PubMed |
description | Background: this study aimed to determine the proportion of people living with HIV (PLWH) with anti-SARS-CoV-2 IgG antibodies in a large sample from a single HIV referral center in Rome, Italy; the time-frame included both the first and the second wave of the Italian COVID-19 pandemic; Methods: we conducted a cross-sectional study on stored cryopreserved samples from 1 March 2020 to 30 November 2020. Total antibodies against SARS-CoV-2 were preliminarily tested using a chemiluminescent immunoassay. Positive results were re-tested with an ELISA assay as an IgG confirmatory test; Results: overall, 1389 samples were analyzed from 1106 PLWH: 69% males, median age 53 years, 94% on antiretroviral treatment, 93% with HIV-RNA < 50 copies/mL, median CD4 cell count 610 cell/µL. Our analysis revealed a total of n = 8 patients who tested IgG positive during the study period. Seroprevalence was equal to 0% in the first months (March–June); this started to increase in July and reached a maximum rate of 1.59% in October 2020. The overall seroprevalence was 0.72% (8/1106, 95% CI 0.37–1.42). Conclusion: our findings from this setting show a low IgG SARS-CoV-2 prevalence among PLWH as compared to data available from the general population. |
format | Online Article Text |
id | pubmed-8303907 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83039072021-07-25 Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak Lombardi, Francesca Ricci, Rosalba Belmonti, Simone Fabbiani, Massimiliano Borghetti, Alberto Baldin, Gianmaria Ciccullo, Arturo Tamburrini, Enrica Visconti, Elena Sanguinetti, Maurizio Di Giambenedetto, Simona Diagnostics (Basel) Article Background: this study aimed to determine the proportion of people living with HIV (PLWH) with anti-SARS-CoV-2 IgG antibodies in a large sample from a single HIV referral center in Rome, Italy; the time-frame included both the first and the second wave of the Italian COVID-19 pandemic; Methods: we conducted a cross-sectional study on stored cryopreserved samples from 1 March 2020 to 30 November 2020. Total antibodies against SARS-CoV-2 were preliminarily tested using a chemiluminescent immunoassay. Positive results were re-tested with an ELISA assay as an IgG confirmatory test; Results: overall, 1389 samples were analyzed from 1106 PLWH: 69% males, median age 53 years, 94% on antiretroviral treatment, 93% with HIV-RNA < 50 copies/mL, median CD4 cell count 610 cell/µL. Our analysis revealed a total of n = 8 patients who tested IgG positive during the study period. Seroprevalence was equal to 0% in the first months (March–June); this started to increase in July and reached a maximum rate of 1.59% in October 2020. The overall seroprevalence was 0.72% (8/1106, 95% CI 0.37–1.42). Conclusion: our findings from this setting show a low IgG SARS-CoV-2 prevalence among PLWH as compared to data available from the general population. MDPI 2021-06-24 /pmc/articles/PMC8303907/ /pubmed/34202510 http://dx.doi.org/10.3390/diagnostics11071154 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lombardi, Francesca Ricci, Rosalba Belmonti, Simone Fabbiani, Massimiliano Borghetti, Alberto Baldin, Gianmaria Ciccullo, Arturo Tamburrini, Enrica Visconti, Elena Sanguinetti, Maurizio Di Giambenedetto, Simona Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak |
title | Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak |
title_full | Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak |
title_fullStr | Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak |
title_full_unstemmed | Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak |
title_short | Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak |
title_sort | seroprevalence of sars-cov-2 antibodies in hiv-infected patients in rome, italy during the covid-19 outbreak |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303907/ https://www.ncbi.nlm.nih.gov/pubmed/34202510 http://dx.doi.org/10.3390/diagnostics11071154 |
work_keys_str_mv | AT lombardifrancesca seroprevalenceofsarscov2antibodiesinhivinfectedpatientsinromeitalyduringthecovid19outbreak AT riccirosalba seroprevalenceofsarscov2antibodiesinhivinfectedpatientsinromeitalyduringthecovid19outbreak AT belmontisimone seroprevalenceofsarscov2antibodiesinhivinfectedpatientsinromeitalyduringthecovid19outbreak AT fabbianimassimiliano seroprevalenceofsarscov2antibodiesinhivinfectedpatientsinromeitalyduringthecovid19outbreak AT borghettialberto seroprevalenceofsarscov2antibodiesinhivinfectedpatientsinromeitalyduringthecovid19outbreak AT baldingianmaria seroprevalenceofsarscov2antibodiesinhivinfectedpatientsinromeitalyduringthecovid19outbreak AT cicculloarturo seroprevalenceofsarscov2antibodiesinhivinfectedpatientsinromeitalyduringthecovid19outbreak AT tamburrinienrica seroprevalenceofsarscov2antibodiesinhivinfectedpatientsinromeitalyduringthecovid19outbreak AT viscontielena seroprevalenceofsarscov2antibodiesinhivinfectedpatientsinromeitalyduringthecovid19outbreak AT sanguinettimaurizio seroprevalenceofsarscov2antibodiesinhivinfectedpatientsinromeitalyduringthecovid19outbreak AT digiambenedettosimona seroprevalenceofsarscov2antibodiesinhivinfectedpatientsinromeitalyduringthecovid19outbreak |